文献速递神经免疫

日本第五次全国调查中多发性硬化与视神经脊髓炎谱系疾病的患病率及所致残疾

Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
PubMed 文献 · Neurology · 2024-10-30

日本第五次全国调查覆盖3799个科室,估算2017年多发性硬化(MS)或视神经脊髓炎谱系疾病(NMOSD)患者共24800例,粗患病率19.6/10万(MS 14.2、NMOSD 5.4),高于2003年第四次调查的7.7/10万;与第四次调查相比,MS和NMOSD患者残疾均有所减轻。

要点

  • 2017年日本MS或NMOSD估算患者24800例,粗患病率19.6/10万,其中MS 14.2、NMOSD 5.4。
  • 与第四次调查相比,MS患者EDSS中位数2.0 vs 2.5,继发进展型比例8.5% vs 15.2%,疾病修正药物使用率63.7% vs 37.2%。
  • NMOSD患者EDSS中位数3.5 vs 3.8、病程8.0年 vs 10.0年,均低于第四次调查的视神经脊髓型MS患者。

核心结论

  • 日本MS(尤其具有经典特征者)和NMOSD患病率呈上升趋势,提示环境因素可能起作用;但MS和NMOSD患者的残疾已有所减轻。
  • 广泛使用多种疾病修正药物可能是MS残疾减轻的因素之一。

研究设计与样本

  • 日本第五次全国调查,一级调查向3799个选定的科室(包括神经内科/内科、儿科和眼科)发放问卷,估算2017年MS或NMOSD患者数量与患病率;二级调查通过第二份问卷收集患者详细特征。
  • 一级调查应答率60.1%,二级调查应答率53.9%。

主要发现

  • MS或NMOSD估算患者总数为24800例,是2003年第四次调查的2.5倍;粗患病率19.6/10万(MS 14.2、NMOSD 5.4),第四次调查为7.7/10万。
  • 与第四次调查的常规MS患者相比,MS患者残疾更轻(EDSS中位数2.0[四分位距1.0-4.5] vs 2.5[1.0-6.0]),继发进展型减少(8.5% vs 15.2%),疾病修正药物使用增加(63.7% vs 37.2%)。
  • 寡克隆带阳性率和MRI满足Barkhof标准(经典MS特征)的比例随出生年份推后而增加。
  • 与第四次调查的视神经脊髓型MS患者相比,NMOSD患者残疾更轻、病程更短(EDSS评分3.5[2.0-5.5] vs 3.8[2.0-6.0];病程8.0[3.9-14.8]年 vs 10.0[5.0-16.0]年)。
  • 在NMOSD患者中,残疾加重与纵向广泛脊髓病灶史和抗AQP4抗体阳性相关,二者均随出生年份推后而减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: All 4 previous nationwide surveys of multiple sclerosis (MS) in Japan were conducted before the discovery of anti-aquaporin-4 (AQP4) antibodies; thus, neuromyelitis optica spectrum disorder (NMOSD) was included in MS, as optic-spinal MS. We aimed to clarify the epidemiologic features and trends of MS and NMOSD in Japan separately using a fifth nationwide survey. METHODS: The primary survey, in which a questionnaire was sent to 3,799 selected departments (including neurology/internal medicine, pediatrics, and ophthalmology), explored the estimated number and prevalence of patients with MS or NMOSD in 2017, and the secondary survey collected detailed characteristics of the patients using a second questionnaire. RESULTS: The response rates for the primary and secondary surveys were 60.1% and 53.9%, respectively. The estimated total number of patients with MS or NMOSD was 24,800, 2.5-fold higher than that in the fourth survey in 2003. The crude prevalence was 19.6 per 100,000 patients (14.2 for MS and 5.4 for NMOSD), compared with 7.7 per 100,000 patients in the fourth survey. Patients with MS showed milder disability (median Expanded Disability Status Scale [EDSS] score: 2.0 [interquartile range 1.0-4.5] vs 2.5 [1.0-6.0]), decreased secondary progression (8.5% vs 15.2%), and increased usage of disease-modifying drugs (63.7% vs 37.2%) compared with those with conventional MS in the fourth survey. The proportions of oligoclonal bands and Barkhof criteria fulfillment on MRI, which are features of classical MS, increased with advancing year of birth. Patients with NMOSD also showed less disability and shorter disease duration than patients with optic-spinal MS in the fourth survey (EDSS score: 3.5 [2.0-5.5] vs 3.8 [2.0-6.0]; disease duration: 8.0 [3.9-14.8] vs 10.0 [5.0-16.0]). Among patients with NMOSD, disability was exacerbated by a history of longitudinally extensive spinal cord lesions and anti-AQP4 antibody positivity, which both decreased with advancing year of birth. DISCUSSION: The prevalences of MS (particularly with classical features) and NMOSD have been increasing in Japan, suggesting the contribution of environmental factors. However, disabilities in patients with MS and NMOSD have been mitigated. Extensive usage of various disease-modifying drugs could be a factor contributing to this disability mitigation in MS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Watanabe M, Isobe N, Niino M, et al. Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey. Neurology. 2024. PMID: 39475688. doi:10.1212/WNL.0000000000209992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。